Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Rhythm Pharmaceuticals Inc (RYTM)

Rhythm Pharmaceuticals Inc (RYTM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,091,561
  • Shares Outstanding, K 43,926
  • Annual Sales, $ 0 K
  • Annual Income, $ -74,060 K
  • 60-Month Beta 0.66
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.65

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.91
  • Number of Estimates 3
  • High Estimate -0.74
  • Low Estimate -1.06
  • Prior Year -0.74
  • Growth Rate Est. (year over year) -22.97%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.73 +29.25%
on 11/21/19
25.84 -1.34%
on 12/10/19
+4.00 (+18.58%)
since 11/08/19
3-Month
19.06 +33.76%
on 10/09/19
25.84 -1.34%
on 12/10/19
+4.22 (+19.81%)
since 09/10/19
52-Week
18.00 +41.64%
on 07/30/19
31.94 -20.18%
on 03/26/19
-2.08 (-7.56%)
since 12/10/18

Most Recent Stories

More News
Rhythm Pharmaceuticals Completes Enrollment of Pivotal Cohort in Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alstrom Syndromes

-- Topline data expected in the fourth quarter of 2020 or early in the first quarter of 2021 --

RYTM : 25.50 (+2.60%)
Rhythm Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

Rhythm Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

RYTM : 25.50 (+2.60%)
Rhythm Pharmaceuticals to Present at Stifel 2019 Healthcare Conference

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that Hunter...

RYTM : 25.50 (+2.60%)
Rhythm Pharmaceuticals Reports Third Quarter 2019 Financial Results

-- Announced Positive Topline Results from Pivotal Phase 3 Clinical Trials Evaluating Setmelanotide in POMC and LEPR Deficiency Obesities --

RYTM : 25.50 (+2.60%)
Rhythm Pharmaceuticals Announces Late-Breaking Data Presentations at ObesityWeek(R) 2019

Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that it...

BKDCF : 0.4700 (+3.16%)
RYTM : 25.50 (+2.60%)
JDRF T1D Fund Appoints Veteran Life Sciences Executive Dr. Steven St. Peter as Managing Director

The JDRF T1D Fund, the venture philanthropy fund focused on accelerating life-changing solutions to cure, prevent, and treat type 1 diabetes (T1D) through catalytic investments, today announced the expansion...

PETX : 4.92 (-0.20%)
RYTM : 25.50 (+2.60%)
SNDX : 8.73 (+0.46%)
PRTO : 0.32 (+5.33%)
Rhythm Pharmaceuticals, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced...

MS : 49.67 (+0.14%)
RYTM : 25.50 (+2.60%)
Rhythm Pharmaceuticals, Inc. Announces Pricing of Public Offering

Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced...

MS : 49.67 (+0.14%)
RYTM : 25.50 (+2.60%)
Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering

Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced...

MS : 49.67 (+0.14%)
RYTM : 25.50 (+2.60%)
Rhythm Pharmaceuticals Provides Update on Research and Development Programs

-- Four new MC4R pathway obesity indications added to Phase 2 Basket Study and enrolling patients --

RYTM : 25.50 (+2.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Strengthening short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade RYTM with:

Business Summary

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result in life-threatening metabolic disorders. The Company's product candidate principally consists of setmelanotide,...

See More

Key Turning Points

2nd Resistance Point 26.48
1st Resistance Point 25.99
Last Price 25.50
1st Support Level 24.86
2nd Support Level 24.22

See More

52-Week High 31.94
Fibonacci 61.8% 26.61
Last Price 25.50
Fibonacci 50% 24.97
Fibonacci 38.2% 23.33
52-Week Low 18.00

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar